<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCR</journal-id><journal-title-group><journal-title>World Journal of Cancer Research</journal-title></journal-title-group><issn pub-type="epub">2164-9049</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/WJCR.2016.64007</article-id><article-id pub-id-type="publisher-id">WJCR-19270</article-id><article-categories><subj-group subj-group-type="heading"><subject>WJCR20160400000_55456956.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  乳腺癌患者根治术后上肢淋巴水肿的管理
  Management of Post-Mastectomy Upper Limb Lymphedema in Patients with Breast Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>蒋</surname><given-names>春儿</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>方正</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>邹</surname><given-names>德宏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>浙江省肿瘤医院，放疗科，浙江 杭州</addr-line></aff><aff id="aff2"><addr-line>浙江省肿瘤医院，乳腺外科，浙江 杭州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>wangfz76@126.com(王方)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>12</month><year>2016</year></pub-date><volume>06</volume><issue>04</issue><fpage>36</fpage><lpage>42</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   淋巴水肿是一种淋巴回流障碍引起的慢性、进展性的并发症。接受过腋窝淋巴结清扫的乳腺癌患者中上肢淋巴水肿发生率为16%~40%。而且在前哨淋巴结清扫患者中只有3.5%出现上肢淋巴水肿。然而上肢淋巴水肿并不是目前新出现的并发症，外科治疗的进展为淋巴水肿的管理提供治疗手段，并改善其疗效。因此本文的目的是对乳腺癌术后上肢水肿的外科治疗手段和目前进展做一综述。 Lymphedema is a chronic, progressive complication caused by an imbalance of lymphatic flow. Upper limb lymphedema has been reported in 16% - 40% of breast cancer patients following axillary lymph node dissection. Furthermore, lymphedema followed sentinel lymph node biopsy alone has been reported in 3.5% of patients. While the disease process is not new, there has been significant progress in the surgical treatment for lymphedema that can offer alternatives and improvements in management. The purpose of this review is to provide a comprehensive overview of the current advances and surgical treatment options for upper limb lymphedema after mastectomy for patients with breast cancer.
    
  
 
</p></abstract><kwd-group><kwd>淋巴水肿，乳腺癌，根治术后，并发症, Lymphedema</kwd><kwd> Breast Cancer</kwd><kwd> Post-Mastectomy</kwd><kwd> Complications</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>乳腺癌患者根治术后上肢淋巴水肿的管理<sup> </sup></title><p>蒋春儿<sup>1</sup>，王方正<sup>2</sup>，邹德宏<sup>1</sup></p><p><sup>1</sup>浙江省肿瘤医院，乳腺外科，浙江 杭州</p><p><sup>2</sup>浙江省肿瘤医院，放疗科，浙江 杭州</p><disp-formula id="hanspub.19270-formula53"><graphic xlink:href="http://html.hanspub.org/file/3-2150090x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2016年11月25日；录用日期：2016年12月11日；发布日期：2016年12月16日</p><disp-formula id="hanspub.19270-formula54"><graphic xlink:href="http://html.hanspub.org/file/3-2150090x7_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>淋巴水肿是一种淋巴回流障碍引起的慢性、进展性的并发症。接受过腋窝淋巴结清扫的乳腺癌患者中上肢淋巴水肿发生率为16%~40%。而且在前哨淋巴结清扫患者中只有3.5%出现上肢淋巴水肿。然而上肢淋巴水肿并不是目前新出现的并发症，外科治疗的进展为淋巴水肿的管理提供治疗手段，并改善其疗效。因此本文的目的是对乳腺癌术后上肢水肿的外科治疗手段和目前进展做一综述。</p><p>关键词 :淋巴水肿，乳腺癌，根治术后，并发症</p><disp-formula id="hanspub.19270-formula55"><graphic xlink:href="http://html.hanspub.org/file/3-2150090x8_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>乳腺癌是目前女性高发恶性肿瘤之一，治疗以手术为主的综合治疗。随着疗效提高，患者生命延长，治疗后并发症逐渐受到重视，其中以乳腺癌根治术后上肢淋巴水肿尤为明显。</p><p>淋巴水肿是由于淋巴回流障碍引起的一种慢性、进展性并发症 [<xref ref-type="bibr" rid="hanspub.19270-ref1">1</xref>] 。一开始只影响皮肤和皮下组织，如果不治疗，进一步加重，直至不可逆损伤 [<xref ref-type="bibr" rid="hanspub.19270-ref2">2</xref>] 。乳腺癌患者中接受腋窝淋巴结清扫后有16%~40%出现上肢淋巴水肿 [<xref ref-type="bibr" rid="hanspub.19270-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.19270-ref4">4</xref>] 。最近，乳腺癌外科治疗中，根据前哨淋巴结情况，决定是否腋窝淋巴结清扫，对于前哨淋巴结阳性的患者进行腋窝淋巴结清扫，避免了很多患者没必要进行腋窝淋巴结清扫 [<xref ref-type="bibr" rid="hanspub.19270-ref5">5</xref>] 。这些研究提出了前哨淋巴结加腋窝淋巴结清扫与单独前哨淋巴结相比是否有生存获益，结果表明增加腋窝淋巴结清扫并没有带来生存获益。因此，没有腋窝淋巴结清扫只行前哨淋巴结清扫的患者中，3.5%~10%出现淋巴水肿 [<xref ref-type="bibr" rid="hanspub.19270-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.19270-ref6">6</xref>] 。尽管这种并发症并不是新出现的，目前在淋巴水肿治疗的手段和疗效提高有重要进展，本文对乳腺癌术后上肢淋巴水肿最新进展和治疗策略做一综述。</p></sec><sec id="s4"><title>2. 淋巴水肿的发病机制及影响因素</title><p>乳腺癌术后上肢淋巴水肿进展准确机制目前并不明确，其形成主要是由于淋巴液循环流动平衡破坏，表现为淋巴液流入量增加或流出量减少。增加淋巴液流入量的因素包括：毛细血管通透性的改变，静脉高压(促进静脉淋巴水肿)，或毛细血管胶体渗透压下降 [<xref ref-type="bibr" rid="hanspub.19270-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.19270-ref7">7</xref>] 。同样，也有许多因素减少淋巴液流出量。这些因素可分为原发性病因包括先天的，早发的和迟发的，以及继发性或获得性病因，其中后一种病因更常见 [<xref ref-type="bibr" rid="hanspub.19270-ref8">8</xref>] 。目前恶性肿瘤及其治疗方法，包括手术和放疗，是引起淋巴水肿的最常见的继发性病因 [<xref ref-type="bibr" rid="hanspub.19270-ref9">9</xref>] 。因此，如肥胖、腋窝手术范围、放射治疗、创伤程度和感染等已被确定为易引起淋巴水肿的因素 [<xref ref-type="bibr" rid="hanspub.19270-ref10">10</xref>] 。</p></sec><sec id="s5"><title>3. 淋巴水肿分级系统</title><p>描述淋巴水肿严重程度的最常见分类系统是由国际淋巴学会(the International Society of Lymphology, ISL)发展的评分系统 [<xref ref-type="bibr" rid="hanspub.19270-ref11">11</xref>] (表1)。另一个常用的系统是不良事件常用术语标准V3.0 (CTCAE) [<xref ref-type="bibr" rid="hanspub.19270-ref12">12</xref>] 。淋巴水肿的早期阶段(ISL 0, CTCAE 1)是由亚临床淋巴液循环障碍表示的，即流出道梗阻。在终末期疾病(ISL III, CTCAE 3-4)，慢性肿胀导致纤维化、柱状四肢、复发性皮炎，最终疣状皮肤变化成为象皮病 [<xref ref-type="bibr" rid="hanspub.19270-ref13">13</xref>] 。CTCAE 4级的特点是进展为恶性肿瘤(淋巴管肉瘤)、截肢或致残性淋巴水肿。</p><p>现在已经被提出了淋巴水肿新的分级方法，并且纳入生活质量的影响因素和淋巴管功能的动态监测 [<xref ref-type="bibr" rid="hanspub.19270-ref14">14</xref>] 。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Current systems for staging lymphedem</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >ISL分期(20)</th><th align="center" valign="middle" >Campisi分期(22)</th><th align="center" valign="middle" >临床特征</th></tr></thead><tr><td align="center" valign="middle" >0或1a</td><td align="center" valign="middle" >1A</td><td align="center" valign="middle" >有可能的淋巴管功能障碍(例如手术后)的存在下没有引起水肿， 四肢体积/一致性之间的没有差异</td></tr><tr><td align="center" valign="middle" >I</td><td align="center" valign="middle" >1B</td><td align="center" valign="middle" >轻度水肿——适当的肢体体位可逆变化</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >持续性水肿——适当的肢体位置部分可逆</td></tr><tr><td align="center" valign="middle" >II</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >持续水肿——逐渐加重，反复急性淋巴管炎</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >4</td><td align="center" valign="middle" >纤维化淋巴水肿伴发淋巴滞留疣，柱状的肢体</td></tr><tr><td align="center" valign="middle" >III</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >严重肢体变形的象皮肿，持续硬化性皮炎，广泛淋巴滞留性疣</td></tr></tbody></table></table-wrap><p>表1. 目前淋巴水肿的分级系统</p></sec><sec id="s6"><title>4. 保守治疗 </title><p>淋巴水肿的一线治疗方法是非手术保守治疗，包括手动淋巴引流，复杂的按摩治疗(complex decongestive therapy, CDT)和使用压缩服装。CDT往往需要每周五次按摩共4~6周并同时进行连续包扎。虽然这些治疗方法可以有效的减缓症状的进展，他们并不解决潜在的病理学本质，而且对许多患者来说治疗仍然效果不佳 [<xref ref-type="bibr" rid="hanspub.19270-ref15">15</xref>] 。此外，许多患者发现CDT和持续使用压缩服装的费用昂贵和过程繁琐 [<xref ref-type="bibr" rid="hanspub.19270-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.19270-ref17">17</xref>] 。这些缺点势必引起一些先进的外科手术治疗方案的发展，包括切除皮肤移植到显微外科技术，包括微血管–淋巴管通路和淋巴结移植。</p></sec><sec id="s7"><title>5. 手术治疗</title><p>目前，对于淋巴水肿手术方式的选择并没有达成共识，手术仅作为非手术治疗失败后的挽救手段。手术技术可以分为两类：还原手术/切除和生理性手术。切除手术即切除病变组织，生理手术则建立或恢复淋巴液转运通路。</p><sec id="s7_1"><title>5.1. 还原手术 </title><sec id="s7_1_1"><title>5.1.1. 切除 </title><p>查尔斯于1901年首次描述了切除或还原手术治疗终末期阴囊的淋巴水肿。他的还原技术包括淋巴水肿组织切除和通过皮肤移植来重建 [<xref ref-type="bibr" rid="hanspub.19270-ref18">18</xref>] 。该技术进一步改进并应用上肢淋巴水肿的治疗 [<xref ref-type="bibr" rid="hanspub.19270-ref19">19</xref>] 。尽管还原技术成功的切除了病变组织，巨大的伤口造成毁容，因此需要皮肤移植来修复 [<xref ref-type="bibr" rid="hanspub.19270-ref20">20</xref>] 。</p></sec><sec id="s7_1_2"><title>5.1.2. 吸脂术 </title><p>吸风辅助脂肪切除术(SAL)或吸脂术的使用已成为一种淋巴水肿患者越来越合适的治疗方法。这种技术的理论基础就是病变组织在水肿进展期(ISL III)发生脂肪沉积。该技术最初用于治疗腋窝淋巴结清扫术后或放射治疗后继发上肢淋巴水肿的乳腺癌患者 [<xref ref-type="bibr" rid="hanspub.19270-ref21">21</xref>] 。布罗森的研究显示环形吸脂术和持续使用压迫疗法后水肿的上肢体积可减少118% [<xref ref-type="bibr" rid="hanspub.19270-ref22">22</xref>] 。这些结果是基于患肢与对侧上肢的体积差，这一体积通过水的位移测量,这些结果可维持到治疗后15年，同时这组患者降低了感染率和提高生活质量。Schaverien报道了相似的结果，5年随访水肿上肢体积减少101%和提高生活质量 [<xref ref-type="bibr" rid="hanspub.19270-ref23">23</xref>] 。</p><p>所有这些研究都强调必须使用压缩服装来维持还原手术后体积。如果没有使用的压缩服装，淋巴液在1年内快速堆积再次引起上肢水肿 [<xref ref-type="bibr" rid="hanspub.19270-ref22">22</xref>] 。这些技术的禁忌症包括活动期的恶性肿瘤、开放性伤口、凝血障碍病史以及病人不愿意穿压缩服。</p></sec></sec><sec id="s7_2"><title>5.2. 生理性手术 </title><p>开展一种生理性手术治疗淋巴水肿，这种治疗包括各种术式，目的在于重建淋巴导管或绕过那些闭塞淋巴管建立侧支通路。</p><sec id="s7_2_1"><title>5.2.1. 干细胞移植</title><p>Hou等 [<xref ref-type="bibr" rid="hanspub.19270-ref24">24</xref>] 基于细胞会导致淋巴管生成和新的淋巴管流的假设，研究干细胞移植作为一种治疗淋巴水肿的手段。15名接受手术未行放疗并继发上肢淋巴水肿的乳腺癌患者将髂嵴干细胞转移到腋下，结果显示与CDT相比，在干细胞移植术后12个月上肢肿胀体积和疼痛有显著减少。Maldnado等 [<xref ref-type="bibr" rid="hanspub.19270-ref25">25</xref>] 进行了一个类似的研究，将干细胞移植到接受过腋窝淋巴结清扫术的淋巴水肿患者的上肢和腋窝，患者被随机分配到移植组或压缩治疗组，这两个组患者(每组10人)在上肢水肿体积减少和疼痛减轻出现相似的疗效。尽管这些研究显示了可喜的成果，他们的小样本与显著意义的有关。这种治疗方法仍然停留在实验阶段。</p></sec><sec id="s7_2_2"><title>5.2.2. 淋巴结移植 </title><p>这项技术包括在正常部位提取正常淋巴结和血管组织，并将其移植到淋巴水肿的肢体。目前有两种理论解释这些技术是如何工作的。一种认为移植的淋巴结诱导周围组织的淋巴管生成，因此提高局部淋巴液吸收 [<xref ref-type="bibr" rid="hanspub.19270-ref26">26</xref>] 。另一种理论认为移植的淋巴结相当于一个泵的功能，通过皮瓣的的动脉流入和静脉流出的流体静力汇集周围的淋巴液 [<xref ref-type="bibr" rid="hanspub.19270-ref27">27</xref>] 。在最近关于带血管的淋巴结移植文献中，Raju和Chang发现，只有12个关于这项技术的英文文献(七个在患者进行的，五个在动物实施) [<xref ref-type="bibr" rid="hanspub.19270-ref28">28</xref>] 。这些研究共有84个患者接受各种皮瓣类型，淋巴结供区，移植部位及评价参数。林等研究表明将腹股沟淋巴结移植到环志手腕背侧，13例患者中12例臂围平均减少了51%，在所有患者中淋巴闪烁造影显示淋巴液流动提高，在11例患者中蜂窝组织炎发生率降低 [<xref ref-type="bibr" rid="hanspub.19270-ref27">27</xref>] 。Dionyssiou D等报道36例乳腺癌术后发生上肢淋巴水肿的患者，随机分为淋巴结移植组和物理治疗组，各18例，患者体积减少分别为57%和18%，同时淋巴结移植降低了患肢的感染和提高肢体功能 [<xref ref-type="bibr" rid="hanspub.19270-ref29">29</xref>] 。</p><p>目前常见的供区包括腹股沟(超浅旋髂深血管)、颏下、锁骨上(颈横)、胸部(胸侧)淋巴结，而腹股沟仍然是最常用的供区部位。除了多个供区部位，在上和下肢有许多的移植部位。上肢包括腋下、肘和手腕。下肢包括脚踝、腹股沟和盖。淋巴结移植后供区并发症的热点问题就是腹股沟淋巴结汇集的反向映射的发展。这种技术最初应用于乳腺外科手术，以防止腋窝淋巴结清扫术后上肢水肿 [<xref ref-type="bibr" rid="hanspub.19270-ref30">30</xref>] [<xref ref-type="bibr" rid="hanspub.19270-ref31">31</xref>] 。使用了两种不同的淋巴结检测方法，引流乳腺的淋巴结与那些手臂引流术中关键的淋巴结不同。</p></sec><sec id="s7_2_3"><title>5.2.3. 淋巴管重建 </title><p>目前，最广泛的生理性手术的研究是淋巴管重建。这些技术绕过阻塞淋巴管，建立与淋巴管–淋巴管或淋巴管–静脉吻合。早期试图避开受累的淋巴结与静脉吻合术。这种技术现在在很大程度上被放弃了，由于在吻合部位淋巴液和静脉血之间的反应所引发的的继发性血栓发生率很高 [<xref ref-type="bibr" rid="hanspub.19270-ref32">32</xref>] 。直接淋巴管–淋巴管吻合通过自体淋巴管图实施 [<xref ref-type="bibr" rid="hanspub.19270-ref33">33</xref>] ，但这通常不是技术的选择，多数文献报道应用淋巴管与静脉吻合(lymphaticovenous anastomoses, LVA)或淋巴管间的静脉移植 [<xref ref-type="bibr" rid="hanspub.19270-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.19270-ref35">35</xref>] 。</p><p>Campisi等人发表了迄今为止规模最大的患者应用外周淋巴管–静脉吻合技术治疗淋巴水肿 [<xref ref-type="bibr" rid="hanspub.19270-ref36">36</xref>] 。1800位手臂或腿部出现淋巴水肿的患者纳入研究。大多数患者被认为是Campisi分期系统中2和3级。少数患者是4和5级。如果在淋巴管壁更健康的早期进行显微外科手术，临床结果更好。87%的患者主观上有改善。83%的患者平均肢体体积减少67%的客观提高。蜂窝组织炎的发生率降低了87%。在随访的患者中，有85%的患者可以停止后续保守的措施。微吻合手术通过淋巴闪烁扫描术进行术后评估：真皮回流减少和新的淋巴途径形成是一个成功的标志。作者强调早期病变、良好的患者治疗依从性及全面的淋巴水肿中心对治疗成功至关重要。</p><p>类似的结果也被Olszewski证明，淋巴管重建术后1100多例患者随访达40年 [<xref ref-type="bibr" rid="hanspub.19270-ref37">37</xref>] 。通过对淋巴水肿的病因，Olszeweki表明了盆腔或腹股沟淋巴结清扫术或放疗后出现淋巴水肿的患者有高达80%的改善(小腿周径和关节运动)，先天性淋巴水肿患者几乎100%有改善。炎性阻塞性淋巴水肿患者40%提高 [<xref ref-type="bibr" rid="hanspub.19270-ref36">36</xref>] 。这些数据表明，健康的远端淋巴管对淋巴重建技术至关重要，而且有必要在慢性纤维化和炎症破坏有功能淋巴管之前建立LVAs。</p><p>最近，随着在超显微外科技术的使用迅速提高，对LVA而言吻合的血管从0.3到0.8毫米 [<xref ref-type="bibr" rid="hanspub.19270-ref38">38</xref>] 。即使疾病晚期仍有存活的和有功能的这一口径淋巴管，并能与同等大小的皮下静脉相吻合，这一点对这些新技术而言很重要 [<xref ref-type="bibr" rid="hanspub.19270-ref39">39</xref>] 。利用荧光淋巴显影法，这些仍有功能的淋巴管可以被识别和用于吻合而被解剖出来 [<xref ref-type="bibr" rid="hanspub.19270-ref40">40</xref>] 。当外科医生对亚毫米淋巴管操作越来越熟练时，技术的改进可以提高效率和在同一病人进行多只淋巴管间吻合 [<xref ref-type="bibr" rid="hanspub.19270-ref41">41</xref>] [<xref ref-type="bibr" rid="hanspub.19270-ref42">42</xref>] 。所有关于超微淋巴管–静脉吻合术的报告说明改善不同程度水肿上肢的臂围。然而，开展这些技术的研究并不是随机研究，而且目前有用的数据仅限于小样本研究。正因为这个，并没有超显微外科使用的参考指南。</p><p>多个研究表明淋巴管–静脉通路和淋巴结移植治疗肢体淋巴水肿的总体效果很好。然而，没有随机对照试验来研究这些技术。此外，由于研究群体有显著的异质性，并没有关于哪些患者从该技术获益最大以及何时进行该技术的规范。有后续随访(持续时间和临床改善措施)和所采用的辅助治疗的差异，这个问题是复杂的 [<xref ref-type="bibr" rid="hanspub.19270-ref43">43</xref>] 。Basta等在最近一篇显微外科治疗外周淋巴水肿的meta分析中指出采用的文献整体不足。尽管有定量和主观的改善的一致证据，这些技术是安全的，在异质患者群体报道的数据与治疗效果及并发症发生情况并不一致。</p></sec></sec></sec><sec id="s8"><title>6. 结论</title><p>淋巴水肿是慢性、进展性的并且不可治愈的临床问题。对于那些终末期(ISL III, Campisi4,5)疾病患者而言，保守的方法是不现实的，因此还原技术是缓解巨大肢体、反复感染和很差生活质量的唯一选择。对于病情较严重(ISL 0-II, Campisi1a-3)的淋巴水肿患者，显微外科技术可以提供肢体体积的改善，降低死亡率，全面改善生活质量，但只有在保守的方法被证明无效的情况下才考虑此技术。</p><p>目前，还没有随机对照试验比较还原技术和生理性手术的疗效。而且，也没有随机对照试验比较淋巴管重建和带血管的淋巴结移植术的效果。基于以上的研究结果和局限性，保守治疗失败的患者应考虑手术干预，而生理干预在执行IRB协议调查后才被考虑。尽管目前文献表明生理外科干预有获益，并有希望改善长期效果，数据是不确定的，并且需要进一步进行随机对照试验。因此，显示淋巴水肿手术治疗后改善患者生活质量的定量人类研究的文件和支持是必不可少的。</p></sec><sec id="s9"><title>文章引用</title><p>蒋春儿,王方正,邹德宏. 乳腺癌患者根治术后上肢淋巴水肿的管理 Management of Post-Mastectomy Upper Limb Lymphedema in Patients with Breast Cancer[J]. 世界肿瘤研究, 2016, 06(04): 36-42. http://dx.doi.org/10.12677/WJCR.2016.64007</p></sec><sec id="s10"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.19270-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Langer, I., Guller, U., Berclaz, G., et al. (2007) Morbidity of Sentinel Lymph Node Biopsy (SLN) Alone versus SLN and Completion Axillary Lymph Node Dissection after Breast Cancer Surgery: A Prospective Swiss Multicenter Study on 659 Patients. Annals of Surgery, 245, 452-461. https://doi.org/10.1097/01.sla.0000245472.47748.ec</mixed-citation></ref><ref id="hanspub.19270-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Rockson, S.G. (2008) Diagnosis and Management of Lymphatic Vascular Disease. Journal of the American College of Cardiology, 52, 799-806. https://doi.org/10.1016/j.jacc.2008.06.005</mixed-citation></ref><ref id="hanspub.19270-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Miller, C.L., Specht, M.C., Skolny, M.N., et al. (2014) Risk of Lymphedema after Mastectomy: Potential Benefit of Applying ACOSOG Z0011 Protocol to Mastectomy Patients. Breast Cancer Research and Treatment, 144, 71-77.  
https://doi.org/10.1007/s10549-014-2856-3</mixed-citation></ref><ref id="hanspub.19270-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Soran, A., Ozmen, T., McGuire, K.P., et al. (2014) The Importance of Detection of Subclinical Lymphedema for the Prevention of Breast Cancer-Related Clinical Lymphedema after Axillary Lymph Node Dissection; a Prospective Observational Study. Lymphatic Research and Biology, 12, 289-294. https://doi.org/10.1089/lrb.2014.0035</mixed-citation></ref><ref id="hanspub.19270-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Fu, Y., Chung, D., Cao, M.A., et al. (2014) Is Axillary Lymph Node Dissection Necessary after Sentinel Lymph Node Biopsy in Patients with Mastectomy and Pathological N1 Breast Cancer? Annals of Surgical Oncology, 21, 4109-4123.  
https://doi.org/10.1245/s10434-014-3814-3</mixed-citation></ref><ref id="hanspub.19270-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Sackey, H., Magnuson, A., Sandelin, K., et al. (2014) Arm Lymphoedema after Axillary Surgery in Women with Invasive Breast Cancer. British Journal of Surgery, 101, 390-397. https://doi.org/10.1002/bjs.9401</mixed-citation></ref><ref id="hanspub.19270-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Bunke, N., Brown, K. and Bergan, J. (2009) Phlebolymphemeda: Usually Unrecognized, Often Poorly Treated. Perspectives in Vascular Surgery and Endovascular Therapy, 21, 65-68. https://doi.org/10.1177/1531003509337155</mixed-citation></ref><ref id="hanspub.19270-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Lee, B., Andrade, M., Bergan, J., et al. (2010) Diagnosis and Treatment of Primary Lymphedema. Consensus Document of the International Union of Phlebology (IUP)-2009. International Angiology, 29, 454-470.</mixed-citation></ref><ref id="hanspub.19270-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Das, N., Baumgartner, R.N., Riley, E.C., et al. (2015) Treatment-Related Risk Factors for Arm Lymphedema among Long-Term Breast Cancer Survivors. Journal of Cancer Survivorship, 9, 422-430.  
https://doi.org/10.1007/s11764-014-0416-9</mixed-citation></ref><ref id="hanspub.19270-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Boughey, J.C., Hoskin, T.L., Cheville, A.L., et al. (2014) Risk Factors Associated with Breast Lymphedema. Annals of Surgical Oncology, 21, 1202-1208. https://doi.org/10.1245/s10434-013-3408-5</mixed-citation></ref><ref id="hanspub.19270-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Coriddi, M., Khansa, I., Stephens, J., Miller, M., Boehmler, J. and Tiwari, P. (2015) Analysis of Factors Contributing to Severity of Breast Cancer-Related Lymphedema. Annals of Plastic Surgery, 74, 22-25.  
https://doi.org/10.1097/SAP.0b013e31828d7285</mixed-citation></ref><ref id="hanspub.19270-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cheville, A.L., McGarvey, C.L., Petrek, J.A., Russo, S.A., Thiadens, S.R.J. and Taylor, M.E. (2003) The Grading of Lymphedema in Oncology Clinical Trials. Seminars in Radiation Oncology, 13, 214-225.  
https://doi.org/10.1016/S1053-4296(03)00038-9</mixed-citation></ref><ref id="hanspub.19270-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Campisi, C. and Boccardo, F. (2004) Microsurgical Techniques for Lymphedema Treatment: Derivative Lymphatic-Venous Microsurgery. World Journal of Surgery, 28, 609-613. https://doi.org/10.1007/s00268-004-7252-4</mixed-citation></ref><ref id="hanspub.19270-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Yamamoto, T., Narushima, M., Doi, K., et al. (2011) Characteristic Indocyanine Green Lymphography Findings in Lower Extremity Lymphedema: The Generation of a Novel Lymphedema Severity Staging System Using Dermal Backflow Patterns. Plastic &amp; Reconstructive Surgery, 127, 1979-1986. https://doi.org/10.1097/PRS.0b013e31820cf5df</mixed-citation></ref><ref id="hanspub.19270-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Do, J.H., Kim, W., Cho, Y.K., et al. (2015) Effects of Resistance Exercises and Complex Decongestive Therapy on Arm Function and Muscular Strength in Breast Cancer Related Lymphedema. Lymphology, 48, 184-196.</mixed-citation></ref><ref id="hanspub.19270-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pekyavaş, N.Ö., Tunay, V.B., Akbayrak, T., Kaya, S. and Karataş, M. (2014) Complex Decongestive Therapy and Taping for Patients with Postmastectomy Lymphedema: A Randomized Controlled Study. European Journal of Oncology Nursing, 18, 585-590. https://doi.org/10.1016/j.ejon.2014.06.010</mixed-citation></ref><ref id="hanspub.19270-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Leung, N., Furniss, D. and Giele, H. (2015) Modern Surgical Management of Breast Cancer Therapy Related Upper Limb and Breast Lymphoedema. Maturitas, 80, 384-390. https://doi.org/10.1016/j.maturitas.2015.01.012</mixed-citation></ref><ref id="hanspub.19270-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Charles, R. (1901) The Surgical Technique and Operative Treatment of Elephantiasis on the Generative Organs Based on a Series of 140 Successful Cases. Indian Medical Gazette, 36, 84-91.</mixed-citation></ref><ref id="hanspub.19270-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Homans, J. (1936) The Treatment of Elephantiasis of the Legs—A Preliminary Report. The New England Journal of Medicine, 215, 1099-1104. https://doi.org/10.1056/NEJM193612102152401</mixed-citation></ref><ref id="hanspub.19270-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Gloviczki, P. (1999) Principles of Surgical Treatment of Chronic Lymphoedema. International Angiology, 18, 42-46.</mixed-citation></ref><ref id="hanspub.19270-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Brorson, H. (2011) Surgical Treatment of Postmastectomy Lymphedema Liposuction. In: Lee, B., Bergan, J. and Rockson, S.G., Eds., Lymphedema: A Concise Compendium of Theory and Practice, Springer, London, 409-416.  
https://doi.org/10.1007/978-0-85729-567-5_50</mixed-citation></ref><ref id="hanspub.19270-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Brorson, H. and Svensson, H. (1998) Liposuction Combined with Controlled Compression Therapy Reduces Arm Lymphedema More Effectively than Controlled Compression Therapy Alone. Plastic &amp; Reconstructive Surgery, 102, 1058-1067. https://doi.org/10.1097/00006534-199809020-00021</mixed-citation></ref><ref id="hanspub.19270-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Schaverien, M.V., Munro, K.J., Baker, P.A. and Munnoch, D.A. (2012) Liposuction for Chronic Lymphoedema of the Upper Limb: 5 Years of Experience. Journal of Plastic, Reconstructive &amp; Aesthetic Surgery, 65, 935-942.  
https://doi.org/10.1016/j.bjps.2012.01.021</mixed-citation></ref><ref id="hanspub.19270-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Hou, C., Wu, X. and Jin, X. (2008) Autologous Bone Marrow Stromal Cells Transplantation for the Treatment of Secondary Arm Lymphedema: A Prospective Controlled Study in Patients with Breast Cancer Related Lymphedema. Japanese Journal of Clinical Oncology, 38, 670-674. https://doi.org/10.1093/jjco/hyn090</mixed-citation></ref><ref id="hanspub.19270-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Maldonado, G.E., Perez, C.A., Covarrubias, E.E., et al. (2011) Autologous Stem Cells for the Treatment of Post-Mas- tectomy Lymphedema: A Pilot Study. Cytotherapy, 13, 1249-1255.  
https://doi.org/10.3109/14653249.2011.594791</mixed-citation></ref><ref id="hanspub.19270-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Becker, C., Arrive, L., Saaristo, A., et al. (2012) Surgical Treatment of Congenital Lymphedema. Clinics in Plastic Surgery, 39, 377-384. https://doi.org/10.1016/j.cps.2012.08.001</mixed-citation></ref><ref id="hanspub.19270-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Lin, C.H., Ali, R., Chen, S.C., et al. (2009) Vascularized Groin Lymph Node Transfer Using the Wrist as a Recipient Site for Management of Postmastectomy Upper Extremity Lymphedema. Plastic &amp; Reconstructive Surgery, 123, 1265- 1275. https://doi.org/10.1097/PRS.0b013e31819e6529</mixed-citation></ref><ref id="hanspub.19270-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Raju, A. and Chang, D.W. (2015) Vascularized Lymph Node Transfer for Treatment of Lymphedema: A Comprehensive Literature Review. Annals of Surgery, 261, 1013-1023. https://doi.org/10.1097/SLA.0000000000000763</mixed-citation></ref><ref id="hanspub.19270-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Dionyssiou, D., Demiri, E., Tsimponis, A., et al. (2016) A Randomized Control Study of Treating Secondary Stage II Breast Cancer-Related Lymphoedema with Free Lymph Node Transfer. Breast Cancer Research and Treatment, 156, 73-79. https://doi.org/10.1007/s10549-016-3716-0</mixed-citation></ref><ref id="hanspub.19270-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Pasko, J.L., Garreau, J., Carl, A., et al. (2015) Axillary Reverse Lymphatic Mapping Reduces Patient Perceived Incidence of Lymphedema after Axillary Dissection in Breast Cancer. The American Journal of Surgery, 209, 890-895.  
https://doi.org/10.1016/j.amjsurg.2015.01.011</mixed-citation></ref><ref id="hanspub.19270-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Yue, T., Zhuang, D., Zhou, P., et al. (2015) A Prospective Study to Assess the Feasibility of Axillary Reverse Mapping and Evaluate Its Effect on Preventing Lymphedema in Breast Cancer Patients. Clinical Breast Cancer, 15, 301-306.  
https://doi.org/10.1016/j.clbc.2015.01.010</mixed-citation></ref><ref id="hanspub.19270-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Dellachà, A., Boccardo, F., Zilli, A., Napoli, F., Fulcheri, E. and Campisi, C. (2000) Unexpected Histopathological Findings in Peripheral Lymphedema. Lymphology, 33, 62-64.</mixed-citation></ref><ref id="hanspub.19270-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Baumeister, R.G. and Siuda, S. (1990) Treatment of Lymphedemas by Microsurgical Lymphatic Grafting: What Is Proved? Plastic &amp; Reconstructive Surgery, 85, 64-74. https://doi.org/10.1097/00006534-199001000-00012</mixed-citation></ref><ref id="hanspub.19270-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Torrisi, J.S., Joseph, W.J., Ghanta, S., et al. (2015) Lymphaticovenous Bypass Decreases Pathologic Skin Changes in Upper Extremity Breast Cancer-Related Lymphedema. Lymphatic Research and Biology, 13, 46-53.  
https://doi.org/10.1089/lrb.2014.0022</mixed-citation></ref><ref id="hanspub.19270-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Boccardo, F., Casabona, F., De Cian, F., et al. (2014) Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) for Primary Surgical Prevention of Breast Cancer-Related Lymphedema: Over 4 Years Follow-Up. Microsurgery, 34, 421-424. https://doi.org/10.1002/micr.22254</mixed-citation></ref><ref id="hanspub.19270-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Campisi, C., Bellini, C., Campisi, C., Accogli, S., Bonioli, E. and Boccardo, F. (2010) Microsurgery for Lymphedema: Clinical Research and Long-Term Results. Microsurgery, 30, 256-260. https://doi.org/10.1002/micr.20737</mixed-citation></ref><ref id="hanspub.19270-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Olszewski, W.L. (2013) Lymphovenous Microsurgical Shunts in Treatment of Lymphedema of Lower Limbs: A 45-Year Experience of One Surgeon/One Center. European Journal of Vascular and Endovascular Surgery, 45, 282-290. https://doi.org/10.1016/j.ejvs.2012.11.025</mixed-citation></ref><ref id="hanspub.19270-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Masia, J., Olivares, L., Koshima, I., et al. (2014) Barcelona Consensus on Supermicrosurgery. Journal of Reconstructive Microsurgery, 30, 53-58. https://doi.org/10.1055/s-0033-1354742</mixed-citation></ref><ref id="hanspub.19270-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Chang, D.W. (2012) Lymphaticovenular Bypass Surgery for Lymphedema Management in Breast Cancer Patients. Handchirurgie•Mikrochirurgie•Plastische Chirurgie, 44, 343-347. https://doi.org/10.1055/s-0032-1323762</mixed-citation></ref><ref id="hanspub.19270-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Koshima, I., Narushima, M., Yamamoto, Y., Mihara, M. and Iida, T. (2012) Recent Advancement on Surgical Treatments for Lymphedema. Annals of Vascular Diseases, 5, 409-415. https://doi.org/10.3400/avd.ra.12.00080</mixed-citation></ref><ref id="hanspub.19270-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Yamamoto, T., Yoshimatsu, H., Narushima, M., et al. (2014) Sequential Anastomosis for Lymphatic Supermicrosurgery: Multiple Lymphaticovenular Anastomoses on Venule. Annals of Plastic Surgery, 73, 46-49.  
https://doi.org/10.1097/SAP.0b013e31826caff1</mixed-citation></ref><ref id="hanspub.19270-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Yamamoto, T., Narushima, M., Yoshimatsu, H., et al. (2014) Minimally Invasive Lymphatic Supermicrosurgery: Indocyanine Green Lymphography-Guided Simultaneous Multisite Lymphaticovenular Anastomoses via Millimeter Skin Incisions. Annals of Plastic Surgery, 72, 67-70. https://doi.org/10.1097/SAP.0b013e3182605580</mixed-citation></ref><ref id="hanspub.19270-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Mehrara, B.J., Zampell, J.C., Suami, H., et al. (2011) Surgical Management of Lymphedema: Past, Present, and Future. Lymphatic Research and Biology, 9, 159-167. https://doi.org/10.1089/lrb.2011.0011</mixed-citation></ref></ref-list></back></article>